Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
426.90M | 263.40M | 78.50M | 131.40M | 46.70M | 21.80M | Gross Profit |
423.60M | 256.80M | 78.50M | 123.20M | 40.70M | 21.80M | EBIT |
-95.60M | -250.20M | -401.50M | -263.20M | -195.30M | -124.86M | EBITDA |
-91.00M | -250.20M | -394.80M | -256.90M | -183.60M | -117.60M | Net Income Common Stockholders |
-46.60M | -198.90M | -367.30M | -271.90M | -183.20M | -111.79M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
954.30M | 1.04B | 1.26B | 1.21B | 1.50B | 688.53M | Total Assets |
1.00B | 1.09B | 1.30B | 1.27B | 1.58B | 717.37M | Total Debt |
10.50M | 9.70M | 3.20M | 5.50M | 5.00M | 4.04M | Net Debt |
-70.50M | -90.80M | -308.50M | -75.80M | -103.30M | -584.33M | Total Liabilities |
341.00M | 529.70M | 644.60M | 703.90M | 799.90M | 75.11M | Stockholders Equity |
660.10M | 561.70M | 660.00M | 564.90M | 781.70M | 642.26M |
Cash Flow | Free Cash Flow | ||||
-252.80M | -261.10M | -350.70M | -280.30M | 554.70M | -96.20M | Operating Cash Flow |
-250.70M | -259.30M | -347.80M | -273.50M | 559.40M | -89.76M | Investing Cash Flow |
232.00M | 34.70M | 203.50M | 242.80M | -1.31B | 164.25M | Financing Cash Flow |
6.20M | 7.90M | 374.70M | 4.70M | 278.60M | 504.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $923.97M | 68.21 | 33.47% | ― | 29.77% | ― | |
64 Neutral | $448.64M | 8.94 | 11.96% | ― | 43.67% | ― | |
59 Neutral | $730.52M | 53.85 | -4.52% | ― | 92.31% | 78.17% | |
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% | |
49 Neutral | $535.03M | ― | -35.41% | ― | -39.92% | 7.38% | |
39 Underperform | $480.08M | ― | ― | -25.10% | -7.06% |
On May 31, 2025, Arvinas, Inc. and Pfizer announced detailed results from their Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant as a monotherapy for ER+/HER2- advanced or metastatic breast cancer. The trial demonstrated a significant improvement in progression-free survival among patients with ESR1 mutations, with vepdegestrant reducing the risk of disease progression or death by 43% compared to fulvestrant. Despite not reaching statistical significance in the intent-to-treat population, the results suggest vepdegestrant’s potential as a best-in-class treatment option. The companies plan to submit a New Drug Application to the FDA in the latter half of 2025, indicating a significant step towards regulatory approval and potential market introduction.
The most recent analyst rating on (ARVN) stock is a Buy with a $87.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
On April 28, 2025, Arvinas presented preclinical data at the AACR annual meeting in Chicago, showcasing the investigational PROTAC BCL6 degrader, ARV-393. The studies demonstrated synergistic antitumor activity and complete tumor regressions when combined with standard chemotherapy, biologics, and investigational small molecule inhibitors in models of high-grade B-cell lymphoma and aggressive diffuse large B-cell lymphoma. These findings highlight the potential for ARV-393 in combination therapies for lymphoma, supporting further evaluation in clinical settings.
On April 4, 2025, Arvinas, Inc. presented promising data from the first-in-human clinical trial of ARV-102, an investigational PROTAC LRRK2 degrader, at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna. The Phase 1 trial demonstrated ARV-102’s ability to penetrate the blood-brain barrier and significantly degrade LRRK2 protein in both central and peripheral systems, with a favorable safety profile. These findings support further evaluation of ARV-102 in treating neurodegenerative diseases like Parkinson’s disease, with a Phase 1 trial in patients already initiated.
On March 11, 2025, Arvinas, Inc. and Pfizer announced positive results from the Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant monotherapy against fulvestrant in patients with ER+/HER2- metastatic breast cancer. The trial met its primary endpoint in the ESR1m population, showing significant improvement in progression-free survival compared to fulvestrant, although it did not achieve statistical significance in the intent-to-treat population. Vepdegestrant was well tolerated, and the trial will continue to assess overall survival as a secondary endpoint. These results may support future regulatory filings and represent a potential advancement in treatment options for patients with advanced breast cancer.